Study on Androgen Receptor and Triple Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter uncontrolled, open-label, prospective, non-comparative randomized,
phase II study. Patients will be randomized between darolutamide in Arm n°1 (two-stage
Simon's design) and capecitabine in Arm n°2 with two patients randomized in Arm n°1 for one
patient randomized in Arm n°2.
The trial population is composed of women over 18 years old with triple-negative and androgen
receptor positive, locally recurrent (unresectable) or metastatic breast cancer.